TOP November 2015 Vol 8 No 4

As a healthcare professional with substantial income-or income potential, you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career.
Copenhagen, Denmark-Intravenous (IV) iron isomaltoside 1000 (Monofer) demonstrated sustained increases in hemoglobin (Hb) and fewer adverse events compared with oral iron sulphate in patients with chemotherapy-induced anemia (CIA), according to research presented by Gunnar Birgegard, MD, PhD, and colleagues at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.
Hollywood, FL-At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, Associate Professor of Dermatology at Weill Cornell Medical College, and an Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, NY, presented some clinical pearls that can guide the management of dermatologic toxicities.
Anders Mellemgaard, MD, Medical Oncologist from the Department of Oncology, Herlev University Hospital, Herlev, Denmark, spoke with The Oncology Pharmacist about his study, "Antiangiogenic-Specific Adverse Events in Patients with Non-Small-Cell Lung Cancer Treated with Nintedanib and Docetaxel," regarding the development of the new compound that is augmenting the effect of chemotherapy by treating the new vasculature.
Two pilot programs have shown success in raising awareness of safety concerns aimed at reducing the utilization of inappropriate testosterone replacement therapy.
The FDA approved sonidegib for all patients with locally advanced basal-cell carcinoma (BCC).
In order to navigate the increasingly collaborative healthcare landscape, pharmacists need to find a place at the table, according to a presentation at the annual Hematology/Oncology Pharmacy Association conference.
The severity and impact of nausea and vomiting (NV) on patients undergoing chemotherapy and radiotherapy is greater than estimated by oncology physicians and nurses, according to research presented by Cheryl Vidall at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.
The addition of nintedanib to docetaxel therapy did not increase the frequency of adverse events associated with antiangiogenic treatment in non-small-cell lung cancer (NSCLC) patients, according to research presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting.
The Annual Meeting of the American Society of Clinical Oncology (ASCO) is the largest and most important oncology specialty meeting in the United States, and arguably the world. More than 30,000 oncology professionals gathered in Chicago, IL, to hear about ground-breaking research, state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Below is a selection of presentations from oral abstracts, posters, and the ASCO education sessions that will be of interest to oncology nurses and advanced practitioners.
Page 2 of 2
Results 11 - 20 of 20